Chemokine network in multiple sclerosis: Role in pathogenesis and targeting for future treatments

Research output: Contribution to journalArticle

Abstract

Multiple sclerosis is the most common inflammatory disorder of the CNS. Evidence suggests that an immunomediated mechanism plays a crucial role during the development of the disease. Currently, two classes of immunomodulatory agents - interferon-β and glatiramer acetate (Copaxone®, Teva Pharmaceutical Industries), have been approved for the long-term treatment of multiple sclerosis. New drugs which effectively target the immunological processes occurring in multiple sclerosis have been proposed. This review summarizes the immunological background that occurs during the pathogenesis of multiple sclerosis focusing on chemokines and related receptors. The effects of standard treatments on the immune system are analyzed along with the current knowledge of potential new immunomodulatory molecules, such as antiadhesion molecules, statins, estriol, cannabinoids, neurotrophic factors and chemokine antagonists.

Original languageEnglish
Pages (from-to)439-453
Number of pages15
JournalExpert Review of Neurotherapeutics
Volume4
Issue number3
DOIs
Publication statusPublished - May 2004

Fingerprint

Chemokines
Multiple Sclerosis
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Estriol
Cannabinoids
Chemokine Receptors
Nerve Growth Factors
Drug Industry
Interferons
Immune System
Pharmaceutical Preparations
Glatiramer Acetate

Keywords

  • Chemokines
  • Immunomodulatory treatments
  • Lymphocytes
  • Multiple sclerosis
  • Receptors

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

@article{9b05e3af42a246d38962d4158aacf08c,
title = "Chemokine network in multiple sclerosis: Role in pathogenesis and targeting for future treatments",
abstract = "Multiple sclerosis is the most common inflammatory disorder of the CNS. Evidence suggests that an immunomediated mechanism plays a crucial role during the development of the disease. Currently, two classes of immunomodulatory agents - interferon-β and glatiramer acetate (Copaxone{\circledR}, Teva Pharmaceutical Industries), have been approved for the long-term treatment of multiple sclerosis. New drugs which effectively target the immunological processes occurring in multiple sclerosis have been proposed. This review summarizes the immunological background that occurs during the pathogenesis of multiple sclerosis focusing on chemokines and related receptors. The effects of standard treatments on the immune system are analyzed along with the current knowledge of potential new immunomodulatory molecules, such as antiadhesion molecules, statins, estriol, cannabinoids, neurotrophic factors and chemokine antagonists.",
keywords = "Chemokines, Immunomodulatory treatments, Lymphocytes, Multiple sclerosis, Receptors",
author = "Daniela Galimberti and Nereo Bresolin and Elio Scarpini",
year = "2004",
month = "5",
doi = "10.1586/14737175.4.3.439",
language = "English",
volume = "4",
pages = "439--453",
journal = "Expert Review of Neurotherapeutics",
issn = "1473-7175",
publisher = "Expert Reviews Ltd.",
number = "3",

}

TY - JOUR

T1 - Chemokine network in multiple sclerosis

T2 - Role in pathogenesis and targeting for future treatments

AU - Galimberti, Daniela

AU - Bresolin, Nereo

AU - Scarpini, Elio

PY - 2004/5

Y1 - 2004/5

N2 - Multiple sclerosis is the most common inflammatory disorder of the CNS. Evidence suggests that an immunomediated mechanism plays a crucial role during the development of the disease. Currently, two classes of immunomodulatory agents - interferon-β and glatiramer acetate (Copaxone®, Teva Pharmaceutical Industries), have been approved for the long-term treatment of multiple sclerosis. New drugs which effectively target the immunological processes occurring in multiple sclerosis have been proposed. This review summarizes the immunological background that occurs during the pathogenesis of multiple sclerosis focusing on chemokines and related receptors. The effects of standard treatments on the immune system are analyzed along with the current knowledge of potential new immunomodulatory molecules, such as antiadhesion molecules, statins, estriol, cannabinoids, neurotrophic factors and chemokine antagonists.

AB - Multiple sclerosis is the most common inflammatory disorder of the CNS. Evidence suggests that an immunomediated mechanism plays a crucial role during the development of the disease. Currently, two classes of immunomodulatory agents - interferon-β and glatiramer acetate (Copaxone®, Teva Pharmaceutical Industries), have been approved for the long-term treatment of multiple sclerosis. New drugs which effectively target the immunological processes occurring in multiple sclerosis have been proposed. This review summarizes the immunological background that occurs during the pathogenesis of multiple sclerosis focusing on chemokines and related receptors. The effects of standard treatments on the immune system are analyzed along with the current knowledge of potential new immunomodulatory molecules, such as antiadhesion molecules, statins, estriol, cannabinoids, neurotrophic factors and chemokine antagonists.

KW - Chemokines

KW - Immunomodulatory treatments

KW - Lymphocytes

KW - Multiple sclerosis

KW - Receptors

UR - http://www.scopus.com/inward/record.url?scp=2342549670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2342549670&partnerID=8YFLogxK

U2 - 10.1586/14737175.4.3.439

DO - 10.1586/14737175.4.3.439

M3 - Article

C2 - 15853541

AN - SCOPUS:2342549670

VL - 4

SP - 439

EP - 453

JO - Expert Review of Neurotherapeutics

JF - Expert Review of Neurotherapeutics

SN - 1473-7175

IS - 3

ER -